Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide in Type 2 Diabetes Inadequately Controlled with Metformin +/- Sulfonylurea
NCT03770728Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Aug 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sanofi. Primary endpoint: Change From Baseline to Week 30 in Glycated Hemoglobin (HbA1c). Started Aug 2019; status: terminated.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03770728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770728.